A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice

A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma (HCC) in Routine Clinical Practice

This trial is a single center observational real-world study. It is planned to include 300 patients with unresectable hepatocellular carcinoma (uHCC) treated with Donafenib. The purpose of the study was to observe the effectiveness and safety of Donafenib in the real world.

Inclusion Criteria:

1. Age ≥ 18 years old;
2. Histologically confirmed HCC or meet the clinical diagnostic criteria of HCC;
3. Unresectable HCC;
4. The doctor decided to use donafenib before the patient was enrolled in the study；
5. Informed consent and willing to complete the study according to the protocol.

Exclusion Criteria:

1. Those who are participating in clinical trials of other antitumor drugs;
2. Allergic to any component of Donafenib tablets;
3. Patients with active bleeding, active peptic ulcer, drug uncontrollable hypertension or severe liver dysfunction;
4. Pregnant or lactating women.